





CMBI Credit Commentary

Fixed Income Daily Market Update 固定收益部市场日报

- The new HSBC Float '29 and HSBC Float '31 tightened 10bps and 20bps from ROs (SOFR+103 and SOFR+129, respectively) this morning, while the new HSBC fixed-rated 29-36s were unchanged. ANZ/WSTP 30-33s widened 1-2bps. NWDEVLs were unchanged to 0.5pt higher. VNKRLEs down another 0.3pt.
- UPLLIN: UPL considers to redeem UPLLIN 5.25 Perp funded by USD bond issuance. UPLLIN 5.25 Perp was up 0.1pts this morning while UPLLIN 28-30s were unchanged. See below.
- NWSZF: CTF Services' adjusted EBITDA dropped by 4.5% yoy to HKD3.6bn (cUSD458mn) in 1HFY25. NWSZF 28-29s were unchanged this morning.
- ❖ Trading desk comments 交易台市场观点

Yesterday, UST yield tightened another 2-5bps and closed 14-20bps tighter WTD. The sentiment remained firm in Chinese IGs. BABA/MEITUA/LENOVO 28-31s closed unchanged to 2bps wider despite RM/PB buying. See our comments on Lenovo's 9MFY25 results on 26 Feb'25. In financials, JP/AU bank papers such as MIZUHO/NAB/WSTP/ANZ 32-36s widened 2-4bps on profit taking. FRESHK 25-28s were unchanged to 2bps tighter on AM buying. In AT1s, DANBNK 7/BACR 7.625 Perps were 0.1-0.3pt higher. Meanwhile, KRKPSC 27-29s tightened 1-3bps. TOPTB 43-48s widened another 2-4bps on RM/PB selling. In HK corps, NWDEVL Perps/27-31s rose another 1.1-2.7pts and closed 2.1-5.4pts higher WTD. Chinese properties were mixed. LNGFOR 28-32s were 0.4-0.8pt higher. CHIOLI 28-43s were up 0.3-0.7pt. VNKRLE 27-29s, however, declined 0.7-0.8pt. In India, UPLLIN 5.25 Perp rose 0.2pt post media reported UPL considers to issue USD bonds to redeem its o/s USD400mn UPLLIN 5.25 Perp. See comments below. ADSEZ 29-31s/ARENERJ 39s/ADGREG 42s were up 0.3-0.6pt.

In LGFVs, there were two way interests on CNH names such as JDZUDG 7.5 28s/QHCTJS 7 28s. In SOE perps, COFCHK/CHPWCN Perps were down 0.1pt.

Glenn Ko, CFA 高志和 (852) 3657 6235 glennko@cmbi.com.hk

Cyrena Ng, CPA 吳蒨瑩 (852) 3900 0801 cyrenang@cmbi.com.hk

Jerry Wang 王世超 (852) 3761 8919 jerrywang@cmbi.com.hk

Last Trading Day's Top Movers

Top Performers	Price	Change
NWDEVL 4 1/8 PERP	31.8	2.7
NWDEVL 4.8 PERP	28.4	2.5
NWDEVL 6 1/4 PERP	31.1	2.5
NWDEVL 6.15 PERP	55.8	2.1
NWDEVL 4 3/4 01/23/27	77.9	1.5

Top Underperformers	Price	Change
VNKRLE 3 1/2 11/12/29	61.3	-0.8
CCAMCL 5 02/08/48	90.5	-0.8
VNKRLE 3.975 11/09/27	71.2	-0.7
CHGDNU 4.8 09/11/48	94.3	-0.4
IIFPTN 1 1/2 01/27/26	95.2	-0.4

❖ Marco News Recap 宏观新闻回顾

Macro – S&P (-0.47%), Dow (+0.37%) and Nasdaq (-1.35%) were mixed on Tuesday. US Feb'25 Conference Board's consumer confidence index was 98.3, lower than the market expectation of 102.7. UST yield retreated on Tuesday, 2/5/10/30 yield at 4.07%/4.12%/4.30%/4.55%.

❖ Desk Analyst Comments 分析员市场观点

UPLLIN: UPL considers to redeem UPLLIN 5.25 Perp funded by USD bond issuance

UPL is considering a USD bond issuance to redeem its UPLLIN 5.25 Perp of USD400mn with a pricing target of below 7%, per media report. The coupon of UPLLIN 5.25 Perp will be reset in May'25 to 5yrUST+3.865% (without step-up), i.e. c7.9% compared with UPL's cost of debts of c7%. As we discussed before, we view the likelihood of the subordinated perp being called by May'25 is higher given the strong 9MFY25 operating results, rights issue and stake sale of Advanta.

We envisage a potential 5-year USD senior unsecured bond to be priced close to the target of UPL, in view of UPLLIN 4.625 06/16/30 is trading at YTM of 6.9% at 90.1. An additional premium would be needed to reflect the structural subordination for a potential USD PerpNC5 issuance, which is the same structure as UPLLIN 5.25 Perp. That said, we do not see a very strong incentive for UPL to call perp if the funding cost is substantially higher than the coupon of the perps after reset in May'25. As per UPL, banks treat UPLLIN 5.25 Perp as equity and this aligns with UPL's accounting treatment. However, the treatment by rating agencies vary. No equity credit was given by Moody's, S&P treats 50% of the principal of the perp as equity up to the first reset date while Fitch removed the 50% equity credit on the perp and accounts the perp as debt on 24 Feb'25 as they view the perp will be redeemed in the short-term.

We maintain neutral on UPLLIN 5.25 Perp on unappealing valuation and thin trading liquidity. At 99.5, UPLLIN 5.25 Perp is trading at yield to reset at 7.5%. For SEA corp perps, we prefer PCORPM 5.95 Perp, SMCGL 5.7 Perp, SMCGL 5.45 Perp, SMCGL 8.125 Perp and SMCPM 5.5 Perp.

Table 1: Bond profiles of UPLLIN

Security name	Amt o/s (USDmn)	Ask px	Ask YTM/ yield to reset	Issue rating (M/S/F)
UPLLIN 5.25 Perp	400	99.5	7.5%	B1/B+/-
UPLLIN 4.5 03/08/28	300	94.1	6.7%	Ba2/BB/BB
UPLLIN 4.625 06/16/30	500	90.1	6.9%	Ba2/BB/BB

Source: Bloomberg.

Offshore Asia New Issues (Priced)

Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
	Size (USD mn)	Size (USD mn) Tenor	Size (USD mn) Tenor Coupon	Size (USD mn) Tenor Coupon Priced

Chengdu Dongfangguangyi Investment Co	170	3yr	5.5%	5.5%	Unrated
Doha Finance Limited	500	5yr	5.25%	T+120	Baa1/-/A
	1500/	4NC3/	4.899%/	T+85/	
	750/	4NC3/	SOFR+103/	SOFR+103/	
HSBC Holdings Plc	1750/	6NC5/	5.13%/	T+105/	A3/A-/A+
-	750/	6NC5/	SOFR+129/	SOFR+129/	
	2250	11NC10	5.45%	T+120	
National Central Cooling Company PJSC (Tabreed)	700	5yr	5.279%	T+115	Baa3/-/-
Zhoukou Urban Construction Investment Development Limited	120	3yr	6.8%	6.8%	Unrated

> Offshore Asia New Issues (Pipeline)

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
	No Offshore	Asia New Issues Pipeli	ne Today		

News and market color

- Regarding onshore primary issuances, there were 101 credit bonds issued yesterday with an amount of RMB145bn. As for month-to-date, 1,179 credit bonds were issued with a total amount of RMB1,113bn raised, representing a 64.4% yoy increase
- China is looking to inject RMB400bn (cUSD55bn) capital into first batch of banks including ABC and BOCOM, mainly funded by issuance of new special sovereign debts
- Hong Kong to cut stamp duty on homes at HKD4mn (cUSD514.5k) or below to HKD100 (cUSD12.9)
- Reserve Bank of India (RBI) revises applicable risk weights on microfinance loans to 100%
- [CQNANA] Chongqing Nan'an District Urban Construction & Development to accept for purchase USD119m of CQNANA 4.98 05/06/25 under tender offer
- [KMLHDM] Kunming Anju Group commences consent solicitation for KMLHDM 8 12/14/25 of USD100mn
- **[LENOVO]** Lenovo 2024 India PC sales rose 7.3% yoy to 2.5mn units according to International Data Corporation
- **[MGFLIN]** Manappuram Finance to reduce the share of its microfinance portfolio to below 15% of its consolidated AUMs to de-risk, from 21% of consolidated AUM as of Dec'24
- **[MUTHIN]** Muthoot Finance gets RBI approval to open 115 new branches
- [NSANY] Nissan Motor downgraded to BB+ from BBB- by Fitch with negative outlook
- **[PWRLNG]** Powerlong is likely to emerge with revised restructuring plan as current scheme set to lapse after 28 Feb'25

• **[SYNGEN]** Syngenta to buy Novartis a genetic repository to boost crop research, the acquisition is expected to close on 1 Jun'25

Fixed Income Department
Tel: 852 3657 6235/ 852 3900 0801
fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended

recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.